News

aTyr Pharma, Inc. filed a current report on November 6, 2026, disclosing the submission of a prospectus supplement to the SEC covering the potential at-the-market sale of common stock with an aggregate offering price of up to $79,994,251.

Gilead Sciences Inc officer Keeley M Cain Wettan filed a Form 144 notice on November 6, 2026, disclosing a proposed sale of 3,399 shares of Gilead common stock acquired through restricted stock unit vesting.

Bowman Consulting Group Ltd. filed post-effective amendments to two Form S-3 registration statements on November 6, 2026, deregistering all remaining unsold securities following the completion of a merger that made the company a wholly-owned subsidiary of Prive Parent, Inc.

Rene Lacerte, a director and officer of BILL Holdings Inc, filed a Form 144 notice on November 6, 2026, proposing the sale of 50,000 shares of common stock on the NYSE through Morgan Stanley Smith Barney LLC Executive Financial Services.

A Form 144 notice of proposed sale was filed on November 6, 2026, disclosing that Makahakama Foundation intends to sell 10,000 shares of BILL Holdings Inc common stock on the NYSE.

Bentley Systems, Incorporated officer Werner Andre filed a Form 144 notice of proposed sale on November 6, 2026, covering 10,000 shares of Class B Common stock on NASDAQ.

Bowman Consulting Group Ltd. filed Post-Effective Amendment No. 1 to two Form S-8 registration statements on November 6, 2026, removing from registration all unsold shares previously registered under its 2021 Omnibus Equity Incentive Plan and 2021 Employee Stock Purchase Plan following the completion of …